However, given the association of PARP-1 and CAF-1/p60 with advanced stages and poor prognosis, respectively, it is possible to hypothesize that a combination of PARP inhibitors and anti-CAF-1/p60 targeted therapy might be effective in MF. The gene discussed is PARP1; the disease is mycosis fungoides.